FDA Nanotech Guidance Draws Industry Comment On Particle Size Criteria
This article was originally published in The Rose Sheet
FDA's draft guidance to industry suggesting that ingredients up to 1 micrometer in size still qualify as nanomaterials if they exhibit “altered properties” should be revised to avoid confusion in the marketplace and promote international harmonization, according to the Personal Care Products Council.
You may also be interested in...
Manufacturers and importers of nanoform substances must meet new REACH information requirements by Jan. 1, 2020, under a regulation adopted by the European Commission Dec. 3. The European Chemicals Agency is considering issuing guidance to support industry’s compliance efforts.
FDA maintains that the current framework for cosmetic safety assessment is sufficient to control potential risks associated with nano-engineered cosmetics. However, traditional testing methods may need to be modified or new strategies developed to account for nanomaterials’ unique properties and behavior, the agency says in final guidance issued June 24.
Members of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology say more light needs to be shed on nanotechnology. FDA officials tell the panel the agency’s understanding of how pharmaceutical firms are using nanotechnology is still developing, but they maintain that currently marketed products are safe.